Find and Pitch Jounalists, Get Your Story Covered

Tags: Isomorphic Labs Eli Lilly

	Profile	Recent Articles on Subject
1	Alex Carchidi Motley Fool Writer, consultant, entrepreneur. Motley Fool. Boston, Massachusetts writingconsultingentrepreneurshipfinance	2 Brand-New Reasons to Buy Eli Lilly Stock Right Now, and 2 Reasons to Be Cautious - 12 days ago Eli Lilly Just Succeeded Where Others Failed, but Does It Matter for the Stock? - 11 months ago Eli Lilly Is Planning to Dominate the Weight Loss Market and Make Billions. Here's Why It'll Keep Winning - about 1 year ago Where Will Eli Lilly Be in 5 Years? - about 1 year ago Eli Lilly Slashed Its Earnings Guidance and Its Stock Went Up 5% Anyway. What's Next? - about 1 year ago
2	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation	Eli Lilly’s Zepbound Leads to Greater Weight Loss vs. Novo Nordisk Drug in Head-to-Head Test - 23 days ago Eli Lilly Plans $4.5B Medicine Foundry to Foster Innovations in Drug Manufacturing - 3 months ago Eli Lilly Moves Closer to Bringing Diabetes Patients a Once-Weekly Insulin Alternative - 4 months ago With Direct-to-Patient Zepbound, Eli Lilly Takes a Stand Against Compounders and PBMs - 4 months ago Eli Lilly Drug Reduces Risk of Diabetes Onset, Building Case for Broader Use of the Therapy - 4 months ago Eli Lilly Shows Appetite for Oral Immunology Drugs, Swallowing Morphic in $3.2B Deal - 6 months ago Eli Lilly Alzheimer’s Drug Lands FDA Approval, Introducing Competition to Eisai’s Leqembi - 6 months ago Eli Lilly Puts $1B on the Line to Expand its Cancer Radiopharmaceuticals Prospects - 6 months ago Eli Lilly Pumps $5.3B More Into Site for Making Metabolic Meds Zepbound & Mounjaro - 7 months ago
3	Mohana Ravindranath STAT News Health tech reporter at STAT. Oakland, CA + Washington, D.C. Health techreporting	Pfizer, Eli Lilly execs push back as senators scrutinize drugmakers’ telehealth moves - 25 days ago
4	Rebecca Pifer Healthcare Dive Reporter @healthcaredive. New York City, United States insurancedigital health	Sanofi joins J&J, Eli Lilly in proposing 340B rebate model - about 1 month ago Eli Lilly follows J&J in suing Biden administration over 340B rebates - about 1 month ago
5	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Pharmalittle: We’re reading about a key Merck drug trial, cheap Wegovy in China, and more - about 1 month ago STAT+: Eli Lilly weight loss drug shortage underscores deeper issues with FDA oversight - 2 months ago STAT+: Pharmalittle: We’re reading about Lilly Alzheimer’s drug adcomm, Amylyx ALS drug flop, and more - 10 months ago STAT+: Pharmalittle: We’re reading about a Lilly obesity-drug ad, a $35 cap on inhalers, and more - 10 months ago STAT+: Pharmalittle: We’re reading about Lilly selling drugs directly, UCB leaving BIO, and more news - 12 months ago STAT+: Pharmalittle: Lilly wins FDA approval for a weight-loss drug; AstraZeneca enters the race for an obesity pill - about 1 year ago STAT+: Pharmalittle: China arrests an Astellas exec accused of spying; weight-loss drugs are being tested in children - about 1 year ago STAT+: Lilly complains to the U.S. International Trade Commission about unapproved versions of Mounjaro - about 1 year ago STAT+: Pharmalittle: Lilly sues spas and compounders over ‘unapproved’ Mounjaro; nasal-spray EpiPen alternative suffers setback - over 1 year ago STAT+: Lilly sues compounders, wellness centers and spas over unapproved versions of Mounjaro - over 1 year ago
6	Lizzy Lawrence STAT News Medical devices reporter at STATnews. Loves news tips. medical reportingnews	STAT+: Eli Lilly weight loss drug shortage underscores deeper issues with FDA oversight - 2 months ago
7	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	STAT+: Eli Lilly weight loss drug shortage underscores deeper issues with FDA oversight - 2 months ago STAT+: Lilly’s Zepbound slashed risk of developing diabetes - 4 months ago As GLP-1 sales surge, insulin users fear Novo Nordisk and Eli Lilly will move on without them - 5 months ago STAT+: Eli Lilly to acquire Morphic for $3.2 billion - 6 months ago Eli Lilly gets FDA approval to sell Mounjaro as obesity drug called Zepbound - about 1 year ago
8	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	FDA’s GLP-1 decision kicks off ‘unprecedented’ tussle over shortage - 2 months ago Lilly lays down $1B to be ‘first in biology’ with obesity gene therapies - 4 months ago Pfizer and Lilly are elbowing into the direct-to-consumer market. Will it work? - 7 months ago
9	Adam Spatacco Motley Fool Community for top investors. Investingcommunity	This is Huge News For Eli Lilly Investors - 2 months ago Eli Lilly Just Made Zepbound Even More Appealing. Here's What Smart Investors Need to Know. - 4 months ago Did Eli Lilly Just Get a Leg Up on Novo Nordisk? - 6 months ago This Is Massive News for Eli Lilly Investors - 6 months ago Move Over, Mounjaro. Eli Lilly Has Another Blockbuster in the Making - 8 months ago Prediction: Eli Lilly and Novo Nordisk Stock Could Just be Getting Started. Here's Why - 10 months ago
10	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	Eli Lilly releases new data on weekly insulin - 4 months ago Lilly has more positive data on its weekly insulin - 4 months ago Eli Lilly’s anti-vanity ad campaign for Oscars - 10 months ago

Journalists covering Eli Lilly